Preparing a Biotech for Investment: The Operating Evidence Investors Need
Connect scientific milestones to accountable leadership, credible capability and transparent assumptions.
Executive summary
An investment narrative should be supported by an operating evidence pack. This article proposes the questions that help founders demonstrate how new resources will translate into deliverable capability.
An evidence-informed advisory paper. The recommendations are Crownbridge's proposed management approaches; this is not an empirical or peer-reviewed study.
In this paper
Turn the narrative into a testable plan
A compelling scientific story needs a clear account of the next milestone and the conditions required to achieve it. Identify the programme owner, technical dependencies, critical appointments and external partners. Distinguish demonstrated facts from assumptions. The UK's Life Sciences Sector Plan highlights scaling and commercialisation challenges [1]; a company's evidence pack should address its own route through those challenges.
Explain what investment will establish: capacity, capability, a development milestone or another specified outcome. Show how management will verify progress and what changes if the preferred sequence fails. Do not present fundraising itself as proof of readiness.
Prepare a proportionate evidence pack
Include the milestone plan, delegation of authority, critical-role coverage, relevant quality arrangements and material supplier dependencies. Add a realistic resource plan and a register of unresolved questions. Make documents consistent so that leadership responsibilities described in the pitch match those used in practice.
For pharmaceutical quality-system questions, ICH Q10 offers a lifecycle reference alongside applicable requirements [2]. The specific obligations depend on the company's activities and phase. Avoid representing a general checklist as regulatory approval or using polished documentation to imply controls that have not been implemented.
Explain gaps honestly
A gap can be manageable if it has an owner, a funded response and a realistic lead time. An unknown dependency requires investigation before its consequence can be priced. Investors should be able to distinguish the two. Present downside scenarios without pretending to know probabilities that cannot be supported.
Crownbridge proposes that founders rehearse the investment discussion around evidence: what is established, what remains uncertain and what the next resources will enable. This operating approach supports assessment; it is not a guarantee of fundraising or a recommendation to invest in a particular business.
Sources & further reading
Public sources consulted 14 October 2026. Source material and Crownbridge recommendations are distinguished in the text.